In summary, our results suggest that, within the tumor, there are cells that are susceptible to TKIs, as well as tumor cells that overexpress molecules—such as CD74 and the DTP-associated lncRNAs—that allow them to resist the initial exposure to these therapeutic drugs, which is linked to intrinsic resistance. Here, CD74 is linked to neoplasm.